Personalized Accelerated Chemoradiation for Lung Cancer
Phase I Trial of Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer
This study is testing a new way to personalize radiation treatment for people with locally advanced lung cancer to see if it works better and is safe.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 45 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Stanford University Academic / other |
| Drugs / interventions | radiation |
| Locations | 2 sites (Palo Alto, California and 1 other locations) |
| Trial ID | NCT06080061 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of hypofractionated accelerated radiation therapy (HART) to treat patients with locally advanced lung cancer. It aims to personalize treatment based on the tumor's location and size, combining radiation with systemic therapy for enhanced effectiveness. The trial will assess the safety and efficacy of this approach in a Phase 1 setting, focusing on patients who meet specific eligibility criteria.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 with documented lung cancer who are eligible for definitive therapy and have a good performance status.
Not a fit: Patients with contraindications to radiotherapy or systemic therapy, or those with certain advanced tumor characteristics, may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a more effective and personalized approach to managing locally advanced lung cancer.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in using accelerated radiation therapy for cancer treatment, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy * ECOG performance status of 0-2 * Age ≥ 18 years old * Ability to understand and the willingness to personally sign the written IRB approved informed consent document * Estimated life expectancy of 12 weeks or longer Exclusion Criteria: * Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist * Age \< 18 years old * Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree * Diagnosis of interstitial pulmonary fibrosis * Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields
Where this trial is running
Palo Alto, California and 1 other locations
- Stanford University — Palo Alto, California, United States (Recruiting)
- Stanford Cancer Center South Bay — San Jose, California, United States (Recruiting)
Study contacts
- Principal investigator: Joseph A Jaoude, MD — Stanford University
- Study coordinator: Aastha Dubey
- Email: adubey7@stanford@stanford.edu
- Phone: 650-725-2084
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.